Side-by-side · Research reference
ChonlutenvsIpamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BPhase 1HUMAN-REVIEWED21/57 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
Ipamorelin
Selective GHRP · Ghrelin Mimetic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Chonluten
Ipamorelin
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998Bowers 1991
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998
Antibody development
—
Not reported in short-term studies
02Dosage Protocols
Parameter
Chonluten
Ipamorelin
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
1–3× per day
Once daily pre-sleep is most common; twice or thrice for advanced users.
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
—
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
8–12 weeks on / 4 weeks off (anecdotal)
GHS-R desensitisation reported with continuous dosing.
Clinical validation
None (PubMed indexed)
—
Standard dose
—
200–300 mcg per injectionRaun 1998
Anecdotal community range; clinical doses 1–3 mg IV in trials.
Lower / starter dose
—
100 mcg per dose
Reconstitution
—
Bacteriostatic water; typical 2 mL per 5 mg vial
Timing
—
Pre-sleep + fasted preferred; 30 min away from food
04Side Effects & Safety
Parameter
Chonluten
Ipamorelin
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Hunger
—
Mild appetite increase via ghrelin-receptor crosstalk
Injection site reaction
—
Mild irritation possible
GH excess (overdose)
—
Joint pain, edema, insulin resistance
IGF-1 elevation
—
Dose-dependent; monitor with chronic high-dose use
Cancer risk
—
Theoretical via GH/IGF-1 axis; contraindicated in active malignancy
Pregnancy / OB
—
Avoid
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
Ipamorelin
- ·Active malignancy or cancer history
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
Ipamorelin
- ·Untreated diabetes
- ·Severe insulin resistance
- ·Concurrent corticosteroid use (theoretical desensitisation)
05Administration Protocol
Parameter
Chonluten
Ipamorelin
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Chonluten
— no documented stacks
Ipamorelin
+ Tesamorelin
StrongIpamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- Tesamorelin
- 2 mg SQ · same injection · pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep depth
+ CJC-1295 (no DAC)
StrongCJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.
- Ipamorelin
- 200–300 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation matching physiological pattern